Betancur et al., TIPS vol. 18, 372-386, 1997.* |
H. Chen, et al., “A Practical and Scalable Synthesis of SR 142801, A Tachykinin NK3 Antagonist”, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 5, pp 555-560, 1997. |
F.-Z. Chung, et al., “Two Classes of Structurally Different Antagonists Display Similar Species Preference for the Human Tachykinin Neurokinin3 Receptor”, Molecular Pharmacology, vol. 48, pp 711-716, 1995. |
R. Patacchini, et al., “Activity of SR 142801 at peripheral tachykinin receptors”, European Journal of Pharmacology, vol. 278, pp 17-25, 1995. |
Y. Tian, et al., “The Unpredicted High Affinities of a Large Number of Naturally Occurring Tachykinins for Chimeric NK1/NK3 Receptors Suggest a Role for an Inhibitory Domain in Determining Receptor Specificity”, The Journal of Biological Chemistry, vol. 271, No. 34, pp 20250-20257, 1996. |
ND Lalwani, et al., “Characterization of tachykinin-mediated calcium mobilisation in CHO-KI cells expressing human NK3 receptor”, Cellular Pharmacology, vol. 2, pp 141-146, 1995. |
Y. Tian, et al., “Structural Motifs Encoded by Individual Exons of the Human Neurokinin-1 Receptor Gene Interact Differentially with Selective Agonists and Antagonists”, Journal of Neurochemistry, vol. 67, No. 2, pp 001-009, 1996. |
S. Nakanishi, “Substance P Precursor and Kininogen: Their Structures, Gene Organizationa, and Regulation”, Physiological Reviews, vol. 67, No. 4, pp 1117-1142, 1987. |
S. Guard and S. Watson, “Tachykinin Receptor Types: Classification and Membrane Signalling Mechanisms”, Neurochem. Int., vol. 18, pp 149-165, 1991. |
S. Nakanishi, “Mammalian Tachykinin Receptors”, Annu. Rev. Neurosci., vol. 14, pp 123-136, 1991. |
B. Pernow, “Substance P”, Pharmacological Reviews, vol. 35, No. 2, pp. 86-141, 1983. |
R. Snider, et al., “A Potent Nonpeptide Antagonist of the Substance P (NK1) Receptor”, Science, vol. 251, pp 435-437, 1991. |
C. Garret, et al., Pharmacological properties of a potent and selective nonpeptide substance P antagonist, Proc. Natl. Acad. Sci. USA, vol. 88, pp 10208-10212, 1991. |
C. Advenier, et al., “Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig”, Br. J. Pharmacol., vol. 105, pp 792-798, 1992. |
A. MacLeod, et al., “N-Acyl-L-tryptophan Benzyl Esters: Potent Substance P Receptor Antagonists”, J. Med. Chem., vol. 36, pp 2044-2045, 1993. |
T. Fujii, et al., “Effect of Novel Substance P Antagonist, FK888, on Airway Constriction and Airway Edema in Guinea-Pigs”, Neuropeptides, p 24, 1992. |
X. Emonds-Alt, et al., “SR 142801, The First Potent N-peptide Antagonist of the Tachykinin NK3 Receptor”, Life Sciences, vol. 56, No. 1, pp. PL 27-32, 1995. |
C. Maggi, et al., “Tachykinin receptors and tachykinin receptor antagonists”, J. Auton. Pharmacol., vol. 13, pp. 23-93, 1993. |
C. Polidori, et al., “Vasopressin release induced by intracranial injection of tachykinins is due to activation of central neurokinin-3 receptors”, Neuroscience Letters, vol. 103, pp 320-325, 1989. |
M. Massi, et al., “The tachykinin NH2-senktide, a selective neurokinin B receptor agonist, is a very potent inhibitor of salt appetite in the rat”, Neuroscience Letters, vol. 92, pp 341-346, 1988. |
G. Improta and M. Broccardo, “Inhibitory Role on Gastric Secretion of a Central NK-3 Tachykinin Receptor Agonist, Senktide”, Peptides, vol. 12, pp 1433-1434, 1991. |
P. Elliott, et al., “Behavioural and Biochemical Responses Following Activation of Midbrain Dopamine Pathways by Receptor Selective Neurokinin Agonists”, Neuropeptides, vol. 19, pp 119-126, 1991. |
A. Stoessl, et al., “The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation”, Psychopharmacology, vol. 95, pp 502-506, 1988. |
A. Stoessl, et al., “Senktide, a selective neurokinin B-like agonist, elicits serotonnin-mediated behaviour following intracisternal administration in the mouse”, Neuroscience Letters, vol. 80, pp 321-326, 1987. |